Innova Captab Limited — PPTs, 05-02-2025: Investor Presentation

Innova Captab Limited is demonstrating strong operational resilience and strategic growth as highlighted in its recent investor presentation for the quarter and nine months ended December 31, 2024. The company reported total income of ₹1,094 crores, with a profit after tax (PAT) of ₹94 crores, marking a 36.3% year-over-year increase in Q3. EBITDA for the quarter was ₹167 crores, reflecting a margin of 15.4%.

The successful commercial launch of operations at its new manufacturing facility in Kathua, Jammu, on January 14, 2025, plays a pivotal role in bolstering production capacity. The site supports 4 manufacturing blocks for various dosage forms, poised for significant revenue contributions, aided by government incentives that enhance profitability.

In terms of strategic initiatives, the acquisition of Sharon Bio-Medicine expands the company's product portfolio significantly into crucial therapeutic areas. Innova Captab is focusing on increasing its market presence both domestically and internationally, aiming for further engagement with 14 out of the 15 top pharmaceutical companies in India. With ongoing expansion and a firm commitment to R&D, investors are presented with a positive outlook for growth in the upcoming years.